Health care providers should know the symptoms of acute flaccid myelitis and immediately hospitalize those who exhibit them, the Centers for Disease Control today said.

AFM mostly affects children and can progress rapidly over the course of hours or days, leading to permanent paralysis and respiratory failure in previously healthy patients. CDC said AFM tends to come in two-year cycles, with the last peak occurring in 2018, hence its new report to provide an anticipatory alert and vital information in preparation of an outbreak this year.

“All clinicians should remain vigilant for AFM and promptly evaluate patients,” said Thomas Clark, M.D., deputy director of CDC’s Division of Viral Diseases. “During the COVID-19 pandemic, this may require adjusting practices to perform clinical evaluations of patients by phone or telemedicine.”

Using 2018 data, the report shows that 98% of AFM patients required hospitalization; 54% were admitted to an intensive care unit and 1 in 4 hospitalized patients needed mechanical ventilation. CDC Director Robert R. Redfield, M.D., in a news briefing today said clinicians should act to prevent worse outcomes by not delaying patients’ hospitalizations.

Related News Articles

Blog
As hospitals and health systems look for sustainable and scalable solutions to help address rising behavioral health needs across the country, digital tools…
Headline
The Centers for Medicare & Medicaid Services Dec. 15 published the Measures Under Consideration List for 2025. These are measures that CMS is considering…
Blog
The holiday season is often depicted as a time of joy and celebration, but for health care professionals it can also be a busy and emotionally demanding time…
Headline
The Centers for Medicare & Medicaid Services Dec. 11 announced the launch of the Make America Healthy Again: Enhancing Lifestyle and Evaluating Value-based…
Headline
The Advisory Committee on Immunization Practices Dec. 5 recommended individual-based decision-making for parents deciding whether to give the hepatitis B…
Headline
Nirsevimab was found to be 80% effective at preventing respiratory syncytial virus-associated intensive care unit admissions during the 2024-2025 RSV season,…